Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A review of FLT3 inhibitors in acute myeloid leukemia
Jennifer Zhao, Sonal Agarwal, Hiba Ahmad, et al.
Blood Reviews (2021) Vol. 52, pp. 100905-100905
Open Access | Times Cited: 122

Showing 1-25 of 122 citing articles:

Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases
Mattias F. Lindberg, Emmanuel Deau, Jonas Arfwedson, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 4106-4130
Closed Access | Times Cited: 25
Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
Yuming Zhang, Lianhai Shan, Wentao Tang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5185-5215
Closed Access | Times Cited: 14
AML treatment: conventional chemotherapy and emerging novel agents
Mark Forsberg, Marina Konopleva
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 5, pp. 430-448
Closed Access | Times Cited: 13
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
Zhiyu Zhang, Jiayi Huang, Zhibo Zhang, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 8
FLT3 -mutated AML: Immune Evasion Through Exosome-Mediated Mechanisms and innovative combination therapies targeting Immune escape
Mohamed J. Saadh, Waleed K. Abdulsahib, Dilfuza Ashurova, et al.
Expert Review of Anticancer Therapy (2025) Vol. 25, Iss. 2, pp. 143-150
Closed Access | Times Cited: 1
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives
Ian M. Bouligny, Keri Maher, Steven Grant
Blood Reviews (2022) Vol. 57, pp. 100996-100996
Open Access | Times Cited: 28
A Review of FLT3 Kinase Inhibitors in AML
Cristina Negotei, Andrei Coliţă, Iuliana Mitu, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6429-6429
Open Access | Times Cited: 22
Bispecific Antibodies in Hematological Malignancies: A Scoping Review
Mohamed H. Omer, Areez Shafqat, Omar Ahmad, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4550-4550
Open Access | Times Cited: 17
Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML
Diana Macečková, Lenka Vaňková, Monika Holubová, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 6
Analysis of a new therapeutic target and construction of a prognostic model for breast cancer based on ferroptosis genes
Qi Li, Hengchen Liu, Yun Jin, et al.
Computers in Biology and Medicine (2023) Vol. 165, pp. 107370-107370
Open Access | Times Cited: 15
FLT3 Mutations in Acute Myeloid Leukemia: Unraveling the Molecular Mechanisms and Implications for Targeted Therapies
Meryem Jalte, Meriame Abbassi, Hinde El Mouhi, et al.
Cureus (2023)
Open Access | Times Cited: 15
Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
Yvyin Zhang, Peihong Wang, Yang Wang, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 13
Novel spiroindoline quinazolinedione derivatives as anticancer agents and potential FLT3 kinase inhibitors
Masoumeh Divar, Najmeh Edraki, Tahereh Damghani, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 90, pp. 117367-117367
Closed Access | Times Cited: 13
Techniques and Strategies in Drug Design and Discovery
George Mihai Nițulescu
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1364-1364
Open Access | Times Cited: 5
Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer
Guillermo Garcia‐Manero, Uwe Platzbecker, Kian‐Huat Lim, et al.
Frontiers in Hematology (2024) Vol. 3
Open Access | Times Cited: 5
A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia
Alireza Mohebbi, Fahimeh Shahriyary, Vida Farrokhi, et al.
Leukemia Research (2024) Vol. 141, pp. 107505-107505
Closed Access | Times Cited: 5
Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern
Annachiara Dozzo, Aoife Galvin, Jae‐Won Shin, et al.
Drug Delivery and Translational Research (2022) Vol. 13, Iss. 8, pp. 2110-2141
Open Access | Times Cited: 22
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
Melisa Tecik, Aysun Adan
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1449-1478
Open Access | Times Cited: 22
Rational discovery of dual FLT3/HDAC inhibitors as a potential AML therapy
Zhijie Wang, Donglin Wu, Xiaofei Zhao, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115759-115759
Closed Access | Times Cited: 12
FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile
Sylvain Garciaz, Marie‐Anne Hospital
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 31-45
Open Access | Times Cited: 11
High FLT3 expression increases immune‐cell infiltration in the tumor microenvironment and correlates with prolonged disease‐free survival in patients with non‐small cell lung cancer
Łukasz Kuncman, Magdalena Orzechowska, Tomasz Milecki, et al.
Molecular Oncology (2024) Vol. 18, Iss. 5, pp. 1316-1326
Open Access | Times Cited: 4
Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia
Malia E. Leifheit, Gunnar Johnson, Timothy M. Kuzel, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9448-9448
Open Access | Times Cited: 4
Histone deacetylase inhibitors for leukemia treatment: current status and future directions
Mohammad‐Salar Hosseini, Zohreh Sanaat, Mohammad Amin Akbarzadeh, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 4
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, et al.
European Journal Of Haematology (2025)
Open Access
Application of a macrocyclization strategy in kinase inhibitor development
Kun Xing, Shujun Li, Jing Li, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top